Published: 2024-01-16


Thank You for 1 Million Reads

Roger Ceilley, James Del Rosso, Boni Elewski, Mark Lebwohl, Joshua Burshtein, Milaan Shah, Danny Zakria

Page 1216

Clinical Management Recommendations

Topical Cycling: The Obstacles to Moving Forward with Systemic Psoriasis Therapies and How to Characterize the Systemic Ready Patient

Milaan Shah, Lauren Miller, Robert Casquejo, TJ Chao, Douglas DiRugierro, Kirk Gautier, Holly Glover, Kristine Kucera, Andrea Nguyen, Leigh Ann Pansch, Joleen Volz, Melodie S. Young, Joshua Burshtein, Danny Zakria

Page 1217-1231


In-Depth Reviews

A Cross-Sectional Analysis of Melanoma-Related Content on TikTok

Shaliz Aflatooni, Kaylee Stankiewicz, Emily Coughlin, Monica Khadka, Paul Rodriguez-Waitkus

Page 1232-1239

Research Letters

Prevalence of Pruritus with Use of Metformin and Other Oral Hypoglycemic Agents

Lauren Sattele, BS, Courtney Linkous, BA, Laura Andrews, MD, MSCR, Chelsea Shope, MD, MSCR, Nicholas Strat, MSCR, Lara Wine Lee, MD, PhD

Page 1258-1261


Brief Articles

The Electronic Health Record: Should Small Practices Adopt this Technology?

Natasha Salmen, Robert Brodell, Lindsey Brodell Dolohanty

Page 1269-1273

Primary Cutaneous Follicle Center Lymphoma in an Adult African American Male

Amanda Arreola, Andraya Gower, Pamela Allen, Joshua Brady, Igor Shendrik

Page 1274-1277

Cyclic Flares of Fever, Rash, and Swelling: A Case Report

Veranca Shah, Hala Rogers, Megan Lockwood, Allison Larson

Page 1278-1282

A Young Woman with a Cystic Mass in the External Auditory Canal

Marcus Stammen, Sonam Rama, Ciaran Smythe, Elliot Lyles, Stephen Olsen

Page 1283-1286

Diffuse Maculopapular Eruption in a Patient with Lemierre’s Syndrome

Hana Iffah Nazir, Aubrey Allen Hess, Kathryn Anne Potter, Loretta Smrtnik Davis

Page 1311-1314

Well-Differentiated Squamous Cell Carcinoma Arising within a Proliferating Pilar Tumor

Patricia Zhao, Lydia A. Luu, Juanita Duran, Alejandro A. Gru, Darren J. Guffey

Page 1315-1318

COVID Concepts

Development of De Novo Pemphigus Vulgaris Following COVID-19 Vaccination

Faraz Yousefian, DO, Farah Tiab, Sujitha Yadlapati, MD, Rodolfo E Chirinos, MD, FAAD, Daniel Rivlin, MD, FAAD

Page 1319-1324

Short Communications

SKINmages: Clinical Images in Dermatology

A Case of Geometric Papules and Plaques within a Tattoo

McKayla Poppens, Walker Mainwaring, Daniel Bach

Page 1340-1342

Reactive Eccrine Syringofibroadenomatosis in the Setting of Venous Insufficiency

Jamie Katy Hu, Loren Hernandez, Gabriel Villada, Alexander Badiavas

Page 1345-1347

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

Generalized Pustular Psoriasis Flares: Treatment Patterns in the Real-World Setting

Megan Noe, Lawrence Rasouliyan, Layla Lavasani, Marianne Laouri, Jamie Rhoads

Page s302

Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials

Andrew Blauvelt, Curdin Conrad, Antonio Costanzo, Peter van de Kerkhof, George Han, Richard G. Langley, Leah Davis, Bengt Hoepken, Susanne Wiegratz, Luis Puig

Page s303

Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials

Joseph F. Merola, Curdin Conrad, Philip Hampton, Jo Lambert, Alice B. Gottlieb, Nicola Tilt, Nancy Cross, Susanne Wiegratz, Melinda Gooderham

Page s304

Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials

Mark Lebwohl, Bruce Strober, Richard G. Langley, Yukari Okubo, Peter Foley, Richard Warren, Luke Peterson, Nancy Cross, Susanne Wiegratz, Delphine Deherder, Diamant Thaçi

Page s305

Bimekizumab 3-year Maintenance of Response in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from Five Phase 3/3b Trials

Diamant Thaçi, April Armstrong, Kenneth B Gordon, Andrew Blauvelt, Carl Paul, Wolf-Henning Boehncke, Maggie Wang, Balint Szilagyi, Bengt Hoepken, Jeremy Lambert, Mark Lebwohl

Page s306

Bimekizumab Efficacy Through 3 Years in Patients with Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from BE BRIGHT

Mark Lebwohl, Bruce Strober, Peter Foley, Richard G. Langley, Yayoi Tada, Philip Hampton, Leah Davis, Susanne Wiegratz, Bengt Hoepken, Jérémy Lambert, Georgios Kokolakis

Page s307

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

Christopher Bunick, Neal Bhatia, James Del Rosso, Zoe Draelos, Lawrence Eichenfield, Leon Kircik, Mark Lebwohl, Melinda Gooderham, Lawrence Green, Adelaide Hebert, Ronald Vender, Matthew Zirwas, Eric Simpson, Linda Stein Gold, Melissa Seal, Scott Snyder, David Osborne, Patrick Burnett, Robert Higham, David Chu, David Berk

Page s309

Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Individual Patient Response from the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

James Del Rosso, H. Chih-ho Hong, Leon Kircik, Melinda Gooderham, Mark Lebwohl, Kim Papp, Linda Stein Gold, Adelaide Hebert, Melissa Seal, David Krupa, David Chu, Patrick Burnett, David Berk, Robert Higham

Page s310

Psoriatic Arthritis

Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry

Philip Mease, Eric Jones, Adam Sima, Silky Beaty, Robert Low, Braulio Gomez, Marie Gurrola, Mark Lebwohl

Page s311

A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 weeks for the Treatment of Psoriatic Arthritis

Richard Warren, Iain McInnes, Peter Nash, Jean-Marie Grouin, Damon Willems, Vanessa Taieb, Jason Eells, Philip Mease

Page s312

Atopic Dermatitis

Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis

Jonathan Silverberg, Thomas Bieber, Amy Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Peter Foley, Erin Johansson, Martin Dossenbach, Bülent Akmaz, Marta Casillas, Andrei Karlsson, Raj Chovatiya

Page s313

Improvement of the Head and Neck Regions with Continuous Tralokinumab treatment for Up to 4 years in Adults with Moderate-to-Severe Atopic Dermatitis

Raj Chovatiya, Andreas Wollenberg, Simone Ribero, Hidehisa Saeki, Christian Øland, Louise Steffensen, Ann-Marie Tindberg, Jacob Thyssen, Andrew Blauvelt

Page s316

Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada

Jashin Wu, Sanjeev Balu, Nikolaj Birk Larsen, Ryan Pulleyblank, Liv Strømkjær, Aron Quah, Marni Wiseman

Page s317

Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities

Amy Paller, Weily Soong, Mark Boguniewicz, Bob Geng, Jacob Thyssen, Aldana Rosso, Louise Steffensen, Shannon Schneider, Andreas Wollenberg

Page s322

Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial

Amy Paller, Michael Cork, Chih-ho Hong, Weilly Soong, Shannon Schneider, Hannah Lo, Line Rosendahl Meldgaard Pedersen, Emilia Vacko, Andreas Wollenberg

Page s323

Neutralizing Interleukin-13 with Tralokinumab Reduces Abundance of S. aureus in Adolescents with Atopic Dermatitis

Lisa Beck, Stephan Weidinger, Marie Tauber, Hidehisa Saeki, Alan Irvine, Lawrence Eichenfield, Thomas Werfel, Petra Arlert, Azra Kurbasic, Mads Røpke, Amy Paller

Page s324

Dupilumab Decreases Concomitant Therapy use in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD

Raj Chovatiya, Jingdong Chao, Chien-Chia Chuang, Min Yang, Brad Shumel, Bruno Martins, Gaelle Bégo-Le-Bagousse, Debra Sierka, Dimittri Delevry

Page s326

Dupilumab Improves Disease Control and Patient-Reported Outcomes in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD

Raj Chovatiya, Jingdong Chao, Chien-Chia Chuang, Min Yang, Brad Shumel, Bruno Martins, Gaelle Bégo-Le-Bagousse, Debra Sierka, Dimittri Delevry

Page s327

Long-Term Efficacy of Abrocitinib in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND

Amy Paller, Michael Cork, Carsten Flohr, Christine Bangert, Stephan Weidinger, John Nesnas, Saleem Farooqui, Pinaki Biswas, Melissa Watkins, Herwig Koppensteiner

Page s329

Patients with Atopic Dermatitis Not on Systemic Therapy have High Rates of Severe, Uncontrolled Disease, and Considerable Impact on Quality of Life

Eric Simpson, Christian Fenske, Alvin Li, Zach Dawson, Yolanda Muñoz Maldonado, Kaylee Ho, Kayla Callahan, Linda Stein Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, Jonathan I Silverberg

Page s330

Pruritus & Prurigo Nodularis

Rapid Reduction and Free or Almost Free of Itch Response With Oral Difelikefalin in Subjects With Notalgia Paresthetica and Moderate-to-Severe Pruritus

Mark Lebwohl, Brian S. Kim, Javier Alonso-Llamazares, Zoe Diana Draelos, Kristine Nograles, Joana Goncalves, Joshua Cirulli, Jennifer A. Mohawk, Catherine Munera, Tom Xue, Robert Bissonnette

Page s331

Symptoms of Neuropathic Itch: A Report From the Neuropathic Itch Patient Survey (NIRVE)

Brian S. Kim, Jennifer A. Mohawk, Joshua Cirulli, Joana Goncalves, Joseph C. Punzalan, Kevin M. Kelly, Mark Lebwohl

Page s332

Skin Cancer

Incorporating the 40-Gene Expression Profile (40-GEP) Test within Each Clinicopathologic Staging System Improves Metastatic Risk-Stratification in Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) and One or More High Risk Factors

Ashley Wysong, Ally‐Khan Somani, Sherrif Ibrahim, Javier Cañueto, Alison Fitzgerald, Jennifer Siegel, Anesh Prasai, Matthew Goldberg, Aaron Farberg, Julia Kasprzak, David Brodland, Shlomo Koyfman, Sarah Arron

Page s334

Health-Related Quality of Life in Patients with Metastatic Basal Cell Carcinoma Treated with Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial

Karl D Lewis, Timothy J Inocencio, Ruben GW Quek, Patrick R LaFontaine, Zeynep Eroglu, Anne Lynn S Chang, Cristina Ivanescu, Alexander J Stratigos, Ketty Peris, Aleksandar Sekulic, Matthew G Fury, Chieh-I Chen

Page s337

Acne & Rosacea

Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis

Linda Stein Gold, Michael Gold, Leon Kircik, Julie Harper, James Del Rosso, Christopher Bunick , Neal Bhatia, Hilary Baldwin, Zoe Draelos, Valerie Callender, Edward Lain

Page s339

Safety and Tolerability of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Black Participants With Acne

Valerie Callender, Fran Cook-Bolden, Leon Kircik, Jonathan Weiss, Andrew Alexis, Michael Gold, Emil Tanghetti, Hilary Baldwin, Linda Stein Gold, Jeffrey Sugarman

Page s340

Topical Clindamycin For Acne Vulgaris: Pharmacovigilance Safety Review and Retrospective Analysis of Gastrointestinal Events

Natalia Pelet del Toro, Andrew Strunk , Jashin Wu, Linda Stein Gold, James Del Rosso, Robert Brodell , George Han

Page s341

Clinician Perception of Antibiotics and Antibiotic Resistance in the Context of Managing Acne Vulgaris (AV), and Satisfaction With AV Treatment Outcomes Among Patients Administered Sarecycline in Clinical Practices Across the US: Results from PROSES Study

James Del Rosso, Linda Stein Gold, Hilary Baldwin, Julie C. Harper, Leon Kircik, Richard G. Fried, Andrew F. Alexis, Evan A. Rieder, Adelaide Hebert, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Emmy Graber

Page s342

Patient and Caregiver Perception of Antibiotics and Antibiotic Resistance in the Context of Managing Acne Vulgaris (AV), and Patient Global Assessment (ptGA) of AV Among Patients Administered Sarecycline in US Clinical Practices: Results from PROSES Study

Adelaide Hebert, Julie C. Harper, Emmy Graber, Evan A. Rieder, Richard G. Fried, Linda Stein Gold, Andrew F. Alexis, Leon Kircik, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Hilary Baldwin

Page s343

Autoimmune Diseases

Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases

Michelle Sholzberg, Kelly Gwathmey, Catherine M. Broome, Matthias Goebeler, Hiroyuki Murai, Zsuzsanna Bata-Csörgo, Adrian Newland, Peter Ulrichts, Rene Kerstens, Jeffrey T. Guptill, Sofiane Agha, Ming Jiang, James F. Howard Jr

Page s344

Overview of Clinical Trials With Efgartigimod in Autoimmune Blistering Diseases: Pemphigus Vulgaris and Pemphigus Foliaceus (ADDRESS and ADDRESS+) and Bullous Pemphigoid (BALLAD and BALLAD+)

Snejina Vassileva, Dedee F. Murrell, Donna A. Culton, Hideyuki Ujiie, Michael Hertl, Matthias Goebeler, Animesh A. Sinha, Enno Schmidt, Ivaylo Stoykov, Peter Verheesen, Luca Borradori, Victoria P. Werth, Pascal Joly

Page s345


Evaluation of Antioxidants’ Ability to Enhance Hyaluronic Acid-Based Topical Moisturizers

Daniel Romanowitz, Dr. Zeichner, Dr. Lain, Dr. Mariwalla, Mr. Kirchner, Ms. Weise, Dr. Draelos

Page s348

Hidradenitis Suppurativa

Bimekizumab Impact on Pain in Moderate to Severe Hidradenitis Suppurativa: Week 16 Results from BE HEARD I & II

Lauren A.V Orenstein, Vivian Shi, Hadar Lev-Tov, Errol Prens, Maurizio Podda, Hideki Fujita, Jeremy Lambert, Robert Rolleri, Edward Muller, Jacek C Szepietowski

Page s350



A Twelve Week Study Evaluating the Efficacy of a Novel Standardized Nutraceutical to Improve Acne and Skin Health

Isabelle Raymond, PhD, Emily Hu. MS, Nicole Townsend, BA, Ryan McLendon, MS, Adina Hazan, PhD

Page s353

Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations

Mahmoud Ghannoum, Ahmed Gamal, Ahmed Kadry , James Del Rosso, Christopher Bunick , Linda Stein Gold, Leon Kircik, Julie Harper

Page s354